Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;28(4):181-8.
doi: 10.1016/j.tibtech.2009.12.007. Epub 2010 Jan 14.

Frontiers in cancer nanomedicine: directing mass transport through biological barriers

Affiliations
Review

Frontiers in cancer nanomedicine: directing mass transport through biological barriers

Mauro Ferrari. Trends Biotechnol. 2010 Apr.

Abstract

The physics of mass transport within body compartments and across biological barriers differentiates cancers from healthy tissues. Variants of nanoparticles can be manufactured in combinatorially large sets, varying by only one transport-affecting design parameter at a time. Nanoparticles can also be used as building blocks for systems that perform sequences of coordinated actions, in accordance with a prescribed logic. We refer to these as Logic-Embedded Vectors (LEVs). Nanoparticles and LEVs are ideal probes for the determination of mass transport laws in tumors, acting as imaging contrast enhancers, and can be employed for lesion-selective delivery of therapy. Their size, shape, density and surface chemistry dominate convective transport in the bloodstream, margination, cell adhesion, selective cellular uptake, as well as sub-cellular trafficking and localization. As argued here, the understanding of transport differentials in cancer, termed 'transport oncophysics', reveals a promising new frontier in oncology: the development of lesion-specific delivery particulates that exploit mass transport differentials to deploy treatment of greater efficacy and reduced side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic illustration of the action of a multi-stage vector
A) A non-toxic, biodegradable first-stage carrier is optimally designed to evade RES and have margination, adhesion, internalization properties that allow it to attain preferential concentration on the target tumor vascular endothelium. (B) The first-stage particle co-releases second-stage carrier nanoparticles with agents that facilitate their permeation through the vascular endothelium into the tumor tissue. (C) The second-stage nanoparticles penetrate the cellular membrane and deploy different, synergistic therapeutic agents into the cytoplasm, the nucleus, or other subcellular targets. The particles themselves can serve as a means for physical therapy, e.g. by converting external radiation (light, radiofrequency, ultrasounds) into heat, for a localized form of thermal ablation.

References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed
    1. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8. - PubMed
    1. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241–63. - PubMed
    1. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989;81:570–6. - PubMed
    1. Sakamoto J, Annapragada A, Decuzzi P, Ferrari M. Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv. 2007;4:359–69. - PubMed

Publication types

MeSH terms

Substances